Sibutramine hydrochloride monohydrate

Sibutramine HCL 10 mg and 15 mg at the best prices!

Sibutramine hydrochloride monohydrate – Sibutramine HCl

Sibutramine, usually available as sibutramine hydrochloride monohydrate, is an orally administered agent for the treatment of obesity, as an appetite suppressant. Sibutramine HCl is a neurotransmitter reuptake inhibitor that reduces the reuptake of serotonin (by 53%), norepinephrine (by 54%), and dopamine (by 16%), thereby increasing the levels of these substances in synaptic clefts and helping enhance satiety; the serotonergic action, in particular, is thought to influence appetite. Older anorectic agents such as amphetamine and fenfluramine force the release of these neurotransmitters rather than affecting their reuptake.

Sibutramine Hydrochloride Monohydrate Indications:

Cardiac valve dysfunction and primary pulmonary hypertension have been associated with the use of centrally acting appetite suppressants. Sibutramine does not promote the release of serotonin (5-hydroxytryptamine, 5-HT) from nerve terminals as do the appetite suppressants that were associated with these adverse events most commonly. A comparison of echocardiograms performed on patients after 0.5 to 16 months (mean 7.6 months) of treatment with 15 mg per day of sibutramine (132 patients) or placebo (77 patients) showed no difference in the incidence of valvular heart disease between the two groups. A second study in 25 patients comparing echocardiograms administered at baseline with those administered after 3 months of treatment with 5 to 30 mg per day of sibutramine detected no cases of valvular heart disease.

In two 12-month studies of sibutramine in obese subjects, maximum weight loss was achieved by 6 months and statistically significant weight loss was maintained over 12 months. Among patients receiving 15 mg per day of sibutramine in clinical weight-loss trials, more than 50% lost ³ 5% of their baseline body weight and about 25% lost ³ 10% of their baseline body weight. However, some weight was regained after discontinuation of sibutramine.

Sibutramine HCl is indicated for the management of obesity, including weight loss and maintenance of weight loss, in patients on a reduced-calorie diet. Sibutramine should be used only in obese patients with an initial body mass index ³ 30 kg of body weight per square meter of height (kg/m 2) or with an initial body mass index ³ 27 kg/m 2 in the presence of other risk factors, such as hypertension, diabetes, or dyslipidemia. Safety and efficacy of sibutramine use for more than 1 year have not been evaluated in controlled trials.

This medicine contains the active ingredient sibutramine hydrochloride monohydrate, which is a type of anti-obesity medicine. In Europe the drug name is Reductil, in US is called Meridia. Recently it is classified as a Schedule IV controlled substance in the United States.

It is in a class of medications called appetite suppressants. It works by acting on appetite control centers in the brain to decrease appetite. No metter on brand name, Sibutramine HCl comes as a capsule to take by mouth.

You will probably lose weight soon after you begin taking sibutramine and following your diet and exercise program. Be sure to monitor your weight, and call your doctor if you do not lose at least 4 pounds during your first 4 weeks of therapy. Your doctor may wish to change your dose of sibutramine. You can order sibutramine without prescription on our website.

You may not continue to lose weight after your first 6 months of treatment. However, you should continue to take it even if you have stopped losing weight. If you stop taking sibutramine, you may gain weight. Do not stop taking sibutramine without talking to your doctor.